Lv11
40 积分 2026-05-12 加入
Investigating SNAC-enhanced peptide drug permeability with stimulated Raman scattering microscopy
4小时前
求助中
FRI0224 Management to reducing liver function impairment when initiating febuxostat for gout based on the prediction nomogram
12天前
已关闭
Metabolic and immunomodulatory control of type 1 diabetes via orally delivered bile-acid-polymer nanocarriers of insulin or rapamycin
17天前
已完结
Controlling Gastric Delivery of a GIP/GLP1 Peptide in Monkeys by Mucoadhesive SNAC Tablets
18天前
已完结
Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors
27天前
已完结
OP0168 CARDIOVASCULAR EVENT ASSOCIATED WITH INITIATING ALLOPURINOL AND FEBUXOSTAT - ACUTE GOUT ATTACK AND CARDIOVASCULAR GOUT ATTACK
28天前
已完结
Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study
28天前
已完结
OP0129 A 12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF RUZINURAD (SHR4640) IN COMBINATION WITH FEBUXOSTAT FOR PRIMARY GOUT AND HYPERURICEMIA WITH AN INADEQUATE RESPONSE TO FEBUXOSTAT ALONE
29天前
已完结
Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study
29天前
已完结
A Drug-Drug Interaction Study of a Novel Selective Urate Reabsorption Inhibitor, SHR4640, and Xanthine Oxidase Inhibitor, Febuxostat, in Patients With Primary Hyperuricemia
30天前
已完结
皖公网安备34019202002308
